|
US8053191B2
(en)
|
2006-08-31 |
2011-11-08 |
Westend Asset Clearinghouse Company, Llc |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
|
JP6118725B2
(ja)
|
2010-11-12 |
2017-04-19 |
ジェン９・インコーポレイテッドＧｅｎ９，ＩＮＣ． |
核酸合成のための方法およびデバイス
|
|
EP2637780B1
(en)
|
2010-11-12 |
2022-02-09 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
|
US10144950B2
(en)
|
2011-01-31 |
2018-12-04 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
|
US11560585B2
(en)
|
2011-01-31 |
2023-01-24 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
|
MX2013010911A
(es)
|
2011-03-23 |
2015-03-03 |
Pioneer Hi Bred Int |
Metodos para producir un locus de rasgo transgenico complejo.
|
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
ES2737957T3
(es)
|
2011-08-26 |
2020-01-17 |
Gen9 Inc |
Composiciones y métodos para el ensamblaje de alta fidelidad de ácidos nucleicos
|
|
EP3604555B1
(en)
|
2011-10-14 |
2024-12-25 |
President and Fellows of Harvard College |
Sequencing by structure assembly
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
|
CA2871505C
(en)
|
2012-04-24 |
2021-10-12 |
Gen9, Inc. |
Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
|
|
CA2869016C
(en)
|
2012-04-25 |
2020-05-05 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
|
EP4570908A3
(en)
|
2012-05-25 |
2025-10-22 |
The Regents of the University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
BR112014031891A2
(pt)
|
2012-06-19 |
2017-08-01 |
Univ Minnesota |
direcionamento genético nas plantas utilizando vírus de dna
|
|
IL236303B
(en)
|
2012-06-25 |
2022-07-01 |
Gen9 Inc |
Methods for high-throughput nucleic acid assembly and sequencing
|
|
CN116064532A
(zh)
|
2012-10-23 |
2023-05-05 |
基因工具股份有限公司 |
用于切割靶dna的组合物及其用途
|
|
SG11201503824SA
(en)
*
|
2012-12-06 |
2015-06-29 |
Sigma Aldrich Co Llc |
Crispr-based genome modification and regulation
|
|
WO2014093595A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas component systems, methods and compositions for sequence manipulation
|
|
EP2784162B1
(en)
|
2012-12-12 |
2015-04-08 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
|
EP2931892B1
(en)
|
2012-12-12 |
2018-09-12 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
WO2014093622A2
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
|
PT2784162E
(pt)
|
2012-12-12 |
2015-08-27 |
Broad Inst Inc |
Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
|
|
DK3064585T3
(da)
|
2012-12-12 |
2020-04-27 |
Broad Inst Inc |
Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
|
|
WO2014093701A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
US10544405B2
(en)
|
2013-01-16 |
2020-01-28 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
CN109913495B
(zh)
|
2013-02-20 |
2022-11-25 |
瑞泽恩制药公司 |
大鼠的遗传修饰
|
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
EP2971167B1
(en)
|
2013-03-14 |
2019-07-31 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
|
MX376838B
(es)
*
|
2013-03-15 |
2025-03-07 |
Univ Minnesota |
Ingenieria genomica de plantas utilizando sistemas crispr/cas.
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
KR102405549B1
(ko)
|
2013-03-15 |
2022-06-08 |
더 제너럴 하스피탈 코포레이션 |
Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
CN105518146B
(zh)
|
2013-04-04 |
2022-07-15 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
|
SMT202100516T1
(it)
|
2013-04-16 |
2021-11-12 |
Regeneron Pharma |
Modificazione mirata del genoma di ratto
|
|
US9873894B2
(en)
*
|
2013-05-15 |
2018-01-23 |
Sangamo Therapeutics, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
US11414695B2
(en)
|
2013-05-29 |
2022-08-16 |
Agilent Technologies, Inc. |
Nucleic acid enrichment using Cas9
|
|
US20140356956A1
(en)
*
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
SG10201913068PA
(en)
*
|
2013-06-04 |
2020-02-27 |
Harvard College |
Rna-guided transcriptional regulation
|
|
RU2716420C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
WO2014204729A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
EP3019595A4
(en)
|
2013-07-09 |
2016-11-30 |
|
THERAPEUTIC USES OF A GENERIC CHANGE WITH CRISPR / CAS SYSTEMS
|
|
WO2015006294A2
(en)
*
|
2013-07-10 |
2015-01-15 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
MX363842B
(es)
|
2013-08-22 |
2019-04-05 |
Du Pont |
Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
|
|
AU2014312123A1
(en)
|
2013-08-29 |
2016-03-17 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for RNA-guided treatment of HIV infection
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
TW201542816A
(zh)
|
2013-09-18 |
2015-11-16 |
Kymab Ltd |
方法、細胞與生物體
|
|
CN110713995B
(zh)
|
2013-10-17 |
2023-08-01 |
桑格摩生物科学股份有限公司 |
用于核酸酶介导的基因组工程改造的递送方法和组合物
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
US10584358B2
(en)
|
2013-10-30 |
2020-03-10 |
North Carolina State University |
Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
|
|
ES2670983T3
(es)
|
2013-11-07 |
2018-06-04 |
Editas Medicine, Inc. |
Métodos y composiciones relacionados con CRISPR con ARNg rectores
|
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
|
BR112016013400B1
(pt)
|
2013-12-11 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc. |
Método in vitro para modificar um genoma em um lócus genômico de interesse em uma célula pluripotente
|
|
EP3080279B1
(en)
|
2013-12-11 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
WO2015089465A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
|
CA2932439A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CA2932478A1
(en)
|
2013-12-12 |
2015-06-18 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
|
|
CA2932436A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
MX375420B
(es)
|
2014-02-11 |
2025-03-06 |
Univ Colorado Regents |
Ingenieria genetica multiplexada habilitada por crispr.
|
|
EP3114227B1
(en)
|
2014-03-05 |
2021-07-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
|
WO2015153780A1
(en)
|
2014-04-02 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
EP3129490A4
(en)
|
2014-04-08 |
2017-10-04 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
|
MX2016014066A
(es)
|
2014-04-28 |
2017-05-03 |
Recombinetics Inc |
Edicion de genes multiples en cerdos.
|
|
AU2015266770A1
(en)
|
2014-05-30 |
2016-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
|
RS60359B1
(sr)
|
2014-06-06 |
2020-07-31 |
Regeneron Pharma |
Postupci i kompozicije za modifikovanje ciljanog lokusa
|
|
MX379237B
(es)
|
2014-06-23 |
2025-03-10 |
Regeneron Pharma |
Ensamblaje de adn mediado por nucleasa.
|
|
WO2015200805A2
(en)
|
2014-06-26 |
2015-12-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
US10179932B2
(en)
|
2014-07-11 |
2019-01-15 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
CN106687594A
(zh)
|
2014-07-11 |
2017-05-17 |
纳幕尔杜邦公司 |
用于产生对草甘膦除草剂具有抗性的植物的组合物和方法
|
|
WO2016011080A2
(en)
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
Crispr/cas transcriptional modulation
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
US20180320226A1
(en)
|
2014-08-19 |
2018-11-08 |
President And Fellows Of Harvard College |
RNA-Guided Systems For Probing And Mapping Of Nucleic Acids
|
|
US9970030B2
(en)
*
|
2014-08-27 |
2018-05-15 |
Caribou Biosciences, Inc. |
Methods for increasing CAS9-mediated engineering efficiency
|
|
US10450584B2
(en)
|
2014-08-28 |
2019-10-22 |
North Carolina State University |
Cas9 proteins and guiding features for DNA targeting and genome editing
|
|
US10570418B2
(en)
|
2014-09-02 |
2020-02-25 |
The Regents Of The University Of California |
Methods and compositions for RNA-directed target DNA modification
|
|
WO2016040594A1
(en)
*
|
2014-09-10 |
2016-03-17 |
The Regents Of The University Of California |
Reconstruction of ancestral cells by enzymatic recording
|
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
|
US9879283B2
(en)
*
|
2014-10-09 |
2018-01-30 |
Life Technologies Corporation |
CRISPR oligonucleotides and gene editing
|
|
AU2015330699B2
(en)
|
2014-10-10 |
2021-12-02 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
CN107002042A
(zh)
|
2014-10-15 |
2017-08-01 |
瑞泽恩制药公司 |
用于产生或维持多能细胞的方法和组合物
|
|
WO2016065341A1
(en)
|
2014-10-24 |
2016-04-28 |
Avectas Limited |
Delivery across cell plasma membranes
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US20170306306A1
(en)
*
|
2014-10-24 |
2017-10-26 |
Life Technologies Corporation |
Compositions and Methods for Enhancing Homologous Recombination
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
MX389266B
(es)
|
2014-11-21 |
2025-03-20 |
Regeneron Pharma |
Metodos y composiciones para la modificacion genetica dirigida mediante el uso de arn guia combinados.
|
|
CN105695485B
(zh)
*
|
2014-11-27 |
2020-02-21 |
中国科学院上海生命科学研究院 |
一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用
|
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
CN107250148B
(zh)
|
2014-12-03 |
2021-04-16 |
安捷伦科技有限公司 |
具有化学修饰的指导rna
|
|
JP6830437B2
(ja)
|
2014-12-10 |
2021-02-17 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
疾患を処置するための遺伝子改変された細胞、組織および臓器
|
|
EP3230451B1
(en)
|
2014-12-12 |
2021-04-07 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
SG11201704646YA
(en)
|
2014-12-19 |
2017-07-28 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
CN107110849B
(zh)
*
|
2014-12-19 |
2019-07-26 |
豪夫迈·罗氏有限公司 |
在选定的细胞亚群中鉴别多个表位的方法
|
|
EP3234111A1
(en)
|
2014-12-19 |
2017-10-25 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
|
EP3702456A1
(en)
|
2014-12-24 |
2020-09-02 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
|
EP3245232B1
(en)
|
2015-01-12 |
2021-04-21 |
The Regents of The University of California |
Heterodimeric cas9 and methods of use thereof
|
|
US11180792B2
(en)
|
2015-01-28 |
2021-11-23 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
EP3250688B1
(fr)
*
|
2015-01-29 |
2021-07-28 |
Meiogenix |
Procede pour induire des recombinaisons meiotiques ciblees
|
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016149422A1
(en)
*
|
2015-03-16 |
2016-09-22 |
The Broad Institute, Inc. |
Encoding of dna vector identity via iterative hybridization detection of a barcode transcript
|
|
CN107567499A
(zh)
|
2015-03-27 |
2018-01-09 |
纳幕尔杜邦公司 |
大豆u6核小rna基因启动子及其在植物小rna基因的组成型表达中的用途
|
|
CN114231527A
(zh)
|
2015-04-06 |
2022-03-25 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
|
US11180793B2
(en)
|
2015-04-24 |
2021-11-23 |
Editas Medicine, Inc. |
Evaluation of Cas9 molecule/guide RNA molecule complexes
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
US11390884B2
(en)
|
2015-05-11 |
2022-07-19 |
Editas Medicine, Inc. |
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
|
|
US11535871B2
(en)
*
|
2015-05-14 |
2022-12-27 |
University Of Southern California |
Optimized gene editing utilizing a recombinant endonuclease system
|
|
AU2016270649B2
(en)
|
2015-05-29 |
2022-04-21 |
North Carolina State University |
Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
CA3000155A1
(en)
|
2015-05-29 |
2016-12-08 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
|
CA2987927C
(en)
|
2015-06-01 |
2024-03-19 |
Temple University - Of The Commonwealth System Of Higher Education |
Methods and compositions for rna-guided treatment of hiv infection
|
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
CN116334142A
(zh)
|
2015-06-09 |
2023-06-27 |
爱迪塔斯医药公司 |
用于改善移植的crispr/cas相关方法和组合物
|
|
KR102902492B1
(ko)
|
2015-06-15 |
2025-12-18 |
노쓰 캐롤라이나 스테이트 유니버시티 |
핵산 및 rna-기반 항미생물제를 효율적으로 전달하기 위한 방법 및 조성물
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
CA2989830A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
|
EP3957731A1
(en)
|
2015-07-15 |
2022-02-23 |
Rutgers, The State University of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
IL257105B
(en)
|
2015-07-31 |
2022-09-01 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
HK1257676A1
(zh)
|
2015-08-28 |
2019-10-25 |
The General Hospital Corporation |
工程化 crispr-cas 9 核酸酶
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
WO2017040511A1
(en)
|
2015-08-31 |
2017-03-09 |
Agilent Technologies, Inc. |
Compounds and methods for crispr/cas-based genome editing by homologous recombination
|
|
WO2017040786A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Massachusetts Institute Of Technology |
Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
|
|
WO2017049129A2
(en)
*
|
2015-09-18 |
2017-03-23 |
President And Fellows Of Harvard College |
Methods of making guide rna
|
|
US20180237800A1
(en)
*
|
2015-09-21 |
2018-08-23 |
The Regents Of The University Of California |
Compositions and methods for target nucleic acid modification
|
|
WO2017053879A1
(en)
|
2015-09-24 |
2017-03-30 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
US10959413B2
(en)
*
|
2015-10-08 |
2021-03-30 |
President And Fellows Of Harvard College |
Multiplexed genome editing
|
|
IL294014B2
(en)
|
2015-10-23 |
2024-07-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
US11111508B2
(en)
|
2015-10-30 |
2021-09-07 |
Brandeis University |
Modified CAS9 compositions and methods of use
|
|
WO2017079406A1
(en)
|
2015-11-03 |
2017-05-11 |
President And Fellows Of Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
|
AU2016353057C1
(en)
|
2015-11-11 |
2021-06-17 |
Regents Of The University Of Minnesota |
Biocontainment/biocontrol system and methods
|
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
CN108779466B
(zh)
|
2015-11-30 |
2024-03-29 |
杜克大学 |
用于通过基因编辑修正人肌营养不良蛋白基因的治疗靶标和使用方法
|
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
|
WO2017115128A2
(en)
|
2015-12-30 |
2017-07-06 |
Avectas Limited |
Vector-free delivery of gene editing proteins and compositions to cells and tissues
|
|
JP7012645B2
(ja)
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
キメラタンパク質および免疫治療の方法
|
|
BR112018013679A2
(pt)
|
2016-01-11 |
2019-01-22 |
Univ Leland Stanford Junior |
proteínas quiméricas e métodos de regulação de expressão gênica
|
|
CN105624187A
(zh)
*
|
2016-02-17 |
2016-06-01 |
天津大学 |
酿酒酵母基因组定点突变的方法
|
|
EP3417061B1
(en)
|
2016-02-18 |
2022-10-26 |
The Regents of the University of California |
Methods and compositions for gene editing in stem cells
|
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
|
EP3429567B1
(en)
|
2016-03-16 |
2024-01-10 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
EP3433362B1
(en)
*
|
2016-03-23 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
US12410416B2
(en)
|
2016-04-19 |
2025-09-09 |
The Broad Institute, Inc. |
CRISPR enzymes and systems with modified pam specificity
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
WO2017189525A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
|
JP2019514379A
(ja)
*
|
2016-04-28 |
2019-06-06 |
インダストリ−アカデミック コオペレーション ファウンデイション， ヨンセイ ユニヴァーシティＩｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ， Ｙｏｎｓｅｉ Ｕｎｉｖｅｒｓｉｔｙ |
Ｒｎａ誘導型ヌクレアーゼ活性のインビボ高スループット評価のための方法
|
|
WO2017201476A1
(en)
|
2016-05-20 |
2017-11-23 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
US12043856B2
(en)
*
|
2016-05-24 |
2024-07-23 |
The Translational Genomics Research Institute |
Molecular tagging methods and sequencing libraries
|
|
BR112018074531B1
(pt)
|
2016-06-02 |
2021-01-19 |
Sigma-Aldrich Co. Llc |
composição que compreende um sistema de nuclease e seu uso, kit, método in vitro para aumentar a eficiência da modificação do genoma-alvo e método para detectar uma sequência cromossômica
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
JP2019518478A
(ja)
|
2016-06-24 |
2019-07-04 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ |
バーコードを付けたコンビナトリアルライブラリーを生成する方法
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
EP3490562B1
(en)
*
|
2016-07-27 |
2025-09-03 |
The Board of Trustees of the Leland Stanford Junior University |
Immolative cell-penetrating complexes for nucleic acid delivery
|
|
CN109563505A
(zh)
*
|
2016-07-28 |
2019-04-02 |
帝斯曼知识产权资产管理有限公司 |
用于真核细胞的组装系统
|
|
SG11201901305YA
(en)
|
2016-07-29 |
2019-03-28 |
Regeneron Pharma |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
|
WO2018026976A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
AU2017324462B2
(en)
|
2016-09-07 |
2024-03-21 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
|
US12499971B2
(en)
|
2016-09-28 |
2025-12-16 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
EA201990861A1
(ru)
|
2016-09-30 |
2019-09-30 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
JP7399710B2
(ja)
|
2016-10-14 |
2023-12-18 |
ザ ジェネラル ホスピタル コーポレイション |
エピジェネティックに調節される部位特異的ヌクレアーゼ
|
|
CN110214180A
(zh)
|
2016-10-14 |
2019-09-06 |
哈佛大学的校长及成员们 |
核碱基编辑器的aav递送
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
EP3541408B1
(en)
|
2016-11-15 |
2024-11-13 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
|
CN110582301A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和蛋白质有效负载递送的方法和组合物
|
|
EP3555297A1
(en)
|
2016-12-19 |
2019-10-23 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
JP7465090B2
(ja)
|
2016-12-22 |
2024-04-10 |
アヴェクタス リミテッド |
可逆的透過処理によるベクターフリー細胞内送達法
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
WO2018129129A1
(en)
|
2017-01-05 |
2018-07-12 |
Rutgers, The State University Of New Jersey |
Targeted gene editing platform independent of dna double strand break and uses thereof
|
|
WO2018129368A2
(en)
|
2017-01-06 |
2018-07-12 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
IL268156B2
(en)
|
2017-01-23 |
2025-01-01 |
Regeneron Pharma |
Variants of 17-beta-hydroxysteroid dehydrogenase and their uses
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
WO2018148440A1
(en)
|
2017-02-08 |
2018-08-16 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
WO2018165631A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
WO2018191520A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
|
US11913015B2
(en)
|
2017-04-17 |
2024-02-27 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
|
CN111031790A
(zh)
|
2017-04-20 |
2020-04-17 |
E开创生物技术股份有限公司 |
产生基因修改的动物的方法
|
|
US12208140B2
(en)
|
2017-04-21 |
2025-01-28 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
|
WO2018204777A2
(en)
|
2017-05-05 |
2018-11-08 |
The Broad Institute, Inc. |
Methods for identification and modification of lncrna associated with target genotypes and phenotypes
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11834665B2
(en)
|
2017-05-10 |
2023-12-05 |
Regents Of The University Of Minnesota |
Programmable transcription factors and methods
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
CA3063449A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
|
EP3635112A2
(en)
|
2017-06-06 |
2020-04-15 |
Zymergen, Inc. |
A htp genomic engineering platform for improving fungal strains
|
|
JP2020524490A
(ja)
|
2017-06-06 |
2020-08-20 |
ザイマージェン インコーポレイテッド |
Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム
|
|
JP7161730B2
(ja)
*
|
2017-06-07 |
2022-10-27 |
国立大学法人 東京大学 |
顆粒状角膜変性症に対する遺伝子治療薬
|
|
KR102746733B1
(ko)
|
2017-06-09 |
2024-12-24 |
에디타스 메디신, 인코포레이티드 |
조작된 cas9 뉴클레아제
|
|
KR20240027153A
(ko)
|
2017-06-15 |
2024-02-29 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
표적화된 비-바이러스 dna 삽입
|
|
MX2019014578A
(es)
|
2017-06-21 |
2020-12-01 |
Timothy A Bertram |
Celulas renales bioactivas inmunoprivilegiadas para el tratamiento de enfermedad renal.
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス，インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
KR102780441B1
(ko)
|
2017-07-31 |
2025-03-17 |
리제너론 파마슈티칼스 인코포레이티드 |
Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
|
|
BR112020001996A2
(pt)
|
2017-07-31 |
2020-08-18 |
Regeneron Pharmaceuticals, Inc. |
animal não humano, e, métodos para testar e para otimizar a capacidade de uma crispr/cas nuclease de excisar um ácido nucleico genômico in vivo, para testar a recombinação induzida por crispr/cas de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo e para otimizar a capacidade de crispr/cas de induzir a recombinação de um ácido nucleico genômico com um ácido nucleico de doador exógeno in vivo.
|
|
CN110891419A
(zh)
|
2017-07-31 |
2020-03-17 |
瑞泽恩制药公司 |
评价crispr/cas-诱导的与外源供体核酸的体内重组
|
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
|
BR112020005323A2
(pt)
|
2017-09-29 |
2020-09-24 |
Intellia Therapeutics, Inc. |
polinucleotídeos, composições e métodos para edição de genoma
|
|
CN111630177A
(zh)
|
2017-09-29 |
2020-09-04 |
英特利亚治疗股份有限公司 |
使用脂质纳米粒子的体外mrna递送方法
|
|
RS65493B1
(sr)
|
2017-09-29 |
2024-05-31 |
Intellia Therapeutics Inc |
Formulacije
|
|
EP3688161A1
(en)
|
2017-09-29 |
2020-08-05 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis
|
|
WO2019067875A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
|
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
|
MY201694A
(en)
|
2017-10-27 |
2024-03-13 |
Univ California |
Targeted replacement of endogenous t cell receptors
|
|
AU2018369784B2
(en)
|
2017-11-14 |
2023-06-01 |
Massachusetts Eye And Ear Infirmary |
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
BR112020014168A2
(pt)
|
2018-01-12 |
2020-12-08 |
Basf Se |
Proteína, ácido nucleico isolado, gene recombinante, vetor, célula hospedeira, planta, parte de planta ou semente de trigo, métodos para produzir, produto de trigo, farinha, farelo integral, amido, grânulos de amido ou farelo de trigo e métodos para identificar e/ou selecionar uma planta de trigo
|
|
EP3740580A4
(en)
|
2018-01-19 |
2021-10-20 |
Duke University |
GENOME ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYONTS
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
US12084676B2
(en)
|
2018-02-23 |
2024-09-10 |
Pioneer Hi-Bred International, Inc. |
Cas9 orthologs
|
|
CA3093702A1
(en)
|
2018-03-14 |
2019-09-19 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CN116349651A
(zh)
|
2018-03-19 |
2023-06-30 |
瑞泽恩制药公司 |
使用crispr/cas系统对动物进行转录调制
|
|
JP7555822B2
(ja)
|
2018-04-19 |
2024-09-25 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
ゲノム編集のための組成物および方法
|
|
KR102852347B1
(ko)
|
2018-05-11 |
2025-09-01 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
|
|
GB2589246A
(en)
|
2018-05-16 |
2021-05-26 |
Synthego Corp |
Methods and systems for guide RNA design and use
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3802779A1
(en)
|
2018-06-01 |
2021-04-14 |
Avectas Limited |
Cell engineering platform
|
|
US12338436B2
(en)
|
2018-06-29 |
2025-06-24 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
EP3820495A4
(en)
|
2018-07-09 |
2022-07-20 |
The Broad Institute Inc. |
RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
|
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
|
EP3830256A2
(en)
|
2018-07-31 |
2021-06-09 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
KR20210053888A
(ko)
|
2018-07-31 |
2021-05-12 |
인텔리아 테라퓨틱스, 인크. |
원발성 고옥살산뇨 1형 (ph1) 치료를 위한 히드록시산 옥시다제 1 (hao1) 유전자 편집을 위한 조성물 및 방법
|
|
CN110678553B
(zh)
*
|
2018-08-21 |
2023-08-11 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
在哺乳动物干细胞中进行基因组编辑的方法
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
KR20210086621A
(ko)
|
2018-09-28 |
2021-07-08 |
인텔리아 테라퓨틱스, 인크. |
락테이트 데히드로게나제 (ldha) 유전자 편집을 위한 조성물 및 방법
|
|
US12203123B2
(en)
|
2018-10-01 |
2025-01-21 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
|
|
WO2020072248A1
(en)
|
2018-10-01 |
2020-04-09 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
US12264313B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
|
|
US12264330B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
BR112021007025A2
(pt)
|
2018-10-16 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para imunoterapia
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
KR20210088615A
(ko)
|
2018-10-31 |
2021-07-14 |
지머젠 인코포레이티드 |
Dna 라이브러리의 다중 결정적 어셈블리
|
|
EP3874048A1
(en)
*
|
2018-11-01 |
2021-09-08 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
AU2019374883A1
(en)
|
2018-11-09 |
2021-05-20 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
EP3894550A4
(en)
|
2018-12-14 |
2023-01-04 |
Pioneer Hi-Bred International, Inc. |
NOVEL CRISPR-CAS SYSTEMS FOR GENOME EDITING
|
|
IL301193A
(en)
|
2018-12-20 |
2023-05-01 |
Regeneron Pharma |
Nuclease-mediated repeat expansion
|
|
EP3911746A1
(en)
|
2019-01-14 |
2021-11-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
VARIANTS OF ADENINE DNA BASES WITH REDUCED OFF-TARGET RNA EDIT
|
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
|
CN113811607A
(zh)
|
2019-03-07 |
2021-12-17 |
加利福尼亚大学董事会 |
CRISPR-Cas效应子多肽和其使用方法
|
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
|
KR20210136997A
(ko)
|
2019-03-08 |
2021-11-17 |
지머젠 인코포레이티드 |
미생물에서 반복적 게놈 편집
|
|
SG11202108091YA
(en)
|
2019-03-18 |
2021-08-30 |
Regeneron Pharma |
Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
|
|
CN113711046B
(zh)
|
2019-03-18 |
2023-08-29 |
瑞泽恩制药公司 |
用于揭示与Tau聚集相关的基因脆弱性的CRISPR/Cas脱落筛选平台
|
|
CA3130488A1
(en)
|
2019-03-19 |
2020-09-24 |
David R. Liu |
Methods and compositions for editing nucleotide sequences
|
|
PH12021552301A1
(en)
|
2019-03-28 |
2022-07-04 |
Intellia Therapeutics Inc |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
|
KR20220004649A
(ko)
|
2019-03-28 |
2022-01-11 |
인텔리아 테라퓨틱스, 인크. |
폴리펩티드 발현을 위한 폴리뉴클레오티드, 조성물 및 방법
|
|
EP3946285A1
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
|
|
CN113727603B
(zh)
|
2019-04-03 |
2024-03-19 |
瑞泽恩制药公司 |
用于将抗体编码序列插入到安全港基因座中的方法和组合物
|
|
IL286917B
(en)
|
2019-04-04 |
2022-09-01 |
Regeneron Pharma |
Methods for scar-free insertion of targeted modifications into targeted vectors
|
|
EP3772929B1
(en)
|
2019-04-04 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized coagulation factor 12 locus
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP7610339B2
(ja)
|
2019-06-04 |
2025-01-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
|
|
TW202112229A
(zh)
|
2019-06-07 |
2021-04-01 |
美商雷傑納榮製藥公司 |
包含人化白蛋白基因座之非人的動物
|
|
US11845957B2
(en)
|
2019-06-14 |
2023-12-19 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
|
CA3152288A1
(en)
|
2019-08-27 |
2021-03-04 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive dna
|
|
KR20220062079A
(ko)
|
2019-09-13 |
2022-05-13 |
리제너론 파마슈티칼스 인코포레이티드 |
지질 나노입자에 의해 전달되는 CRISPR/Cas 시스템을 사용한 동물에서의 전사 조절
|
|
CA3151563A1
(en)
|
2019-09-20 |
2021-03-25 |
Feng Zhang |
Novel type vi crispr enzymes and systems
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
US20230075587A1
(en)
*
|
2019-11-01 |
2023-03-09 |
Suzhou QI Biodesign Biotechnology |
Method for targeted modification of sequence of plant genome
|
|
CN114746125B
(zh)
|
2019-11-08 |
2025-08-08 |
瑞泽恩制药公司 |
用于x连锁青少年型视网膜劈裂症疗法的crispr和aav策略
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
US20230002455A1
(en)
|
2019-11-29 |
2023-01-05 |
Basf Se |
Increasing resistance against fungal infections in plants
|
|
WO2021122687A1
(en)
|
2019-12-19 |
2021-06-24 |
Basf Se |
Increasing space-time-yield, carbon-conversion-efficiency and carbon substrate flexibility in the production of fine chemicals
|
|
JP2023508871A
(ja)
|
2019-12-20 |
2023-03-06 |
ビーエーエスエフ ソシエタス・ヨーロピア |
テルペンの毒性の低減および微生物中での生成可能性の増大
|
|
US11060141B1
(en)
|
2019-12-23 |
2021-07-13 |
Stilla Technologies |
Multiplex drop-off digital polymerase chain reaction methods
|
|
WO2021158858A1
(en)
|
2020-02-07 |
2021-08-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for kallikrein ( klkb1) gene editing
|
|
JP2023515671A
(ja)
|
2020-03-04 |
2023-04-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
免疫療法に対する腫瘍細胞の感作のための方法及び組成物
|
|
US20210290757A1
(en)
|
2020-03-23 |
2021-09-23 |
Avectas Limited |
Engineering of dendritic cells for generation of vaccines against sars-cov-2
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
US12057197B2
(en)
|
2020-04-03 |
2024-08-06 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
|
US20230340538A1
(en)
|
2020-04-08 |
2023-10-26 |
Astrazeneca Ab |
Compositions and methods for improved site-specific modification
|
|
IL297550A
(en)
|
2020-04-28 |
2022-12-01 |
Intellia Therapeutics Inc |
Methods for in vitro cell delivery
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
EP4179079A1
(en)
|
2020-07-10 |
2023-05-17 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
WO2022056000A1
(en)
|
2020-09-09 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of duchenne muscular dystrophy
|
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
|
CA3191387A1
(en)
|
2020-09-30 |
2022-04-07 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
|
WO2022087235A1
(en)
|
2020-10-21 |
2022-04-28 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
|
US20230414648A1
(en)
|
2020-11-06 |
2023-12-28 |
Vertex Pharmaceuticals Incorporated |
Compositions and Methods for Treatment of DM1 with SLUCAS9 and SACAS9
|
|
US20240002839A1
(en)
|
2020-12-02 |
2024-01-04 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
MX2023006878A
(es)
|
2020-12-11 |
2023-07-31 |
Intellia Therapeutics Inc |
Composiciones y métodos para reducir el mhc de clase ii en una célula.
|
|
AU2021409732A1
(en)
|
2020-12-23 |
2023-07-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for reducing hla-a in a cell
|
|
EP4267723A1
(en)
|
2020-12-23 |
2023-11-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying ciita in a cell
|
|
JP2024501757A
(ja)
|
2021-01-05 |
2024-01-15 |
ホライズン・ディスカバリー・リミテッド |
遺伝子組換え細胞の製造方法
|
|
JP2024505084A
(ja)
|
2021-02-01 |
2024-02-02 |
アヴェクタス リミテッド |
送達プラットフォーム
|
|
EP4288548A4
(en)
*
|
2021-02-05 |
2025-01-15 |
Dharmacon, Inc. |
FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION
|
|
EP4288089A2
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
|
EP4288525A1
(en)
|
2021-02-08 |
2023-12-13 |
Intellia Therapeutics, Inc. |
Natural killer cell receptor 2b4 compositions and methods for immunotherapy
|
|
JP2024505678A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス，インコーポレイテッド |
免疫療法のためのリンパ球活性化遺伝子３（ｌａｇ３）組成物及び方法
|
|
WO2022182957A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
|
US20240182890A1
(en)
|
2021-04-07 |
2024-06-06 |
Astrazeneca Ab |
Compositions and methods for site-specific modification
|
|
US20220331361A1
(en)
*
|
2021-04-07 |
2022-10-20 |
Century Therapeutics, Inc. |
Gene transfer vectors and methods of engineering cells
|
|
KR20240017791A
(ko)
|
2021-04-17 |
2024-02-08 |
인텔리아 테라퓨틱스, 인크. |
Dna-의존적 단백질 키나제의 억제제 및 이의 조성물 및 용도
|
|
US20240200106A1
(en)
|
2021-04-17 |
2024-06-20 |
Intellia Thrapeutics, Inc. |
Lipid nanoparticles compositions
|
|
BR112023021477A2
(pt)
|
2021-04-17 |
2024-01-30 |
Intellia Therapeutics Inc |
Composições de nanopartículas lipídicas
|
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
|
WO2022240846A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
KR20240027676A
(ko)
|
2021-06-02 |
2024-03-04 |
라이엘 이뮤노파마, 인크. |
Nr4a3-결핍 면역 세포 및 이의 용도
|
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
|
WO2023028471A1
(en)
|
2021-08-24 |
2023-03-02 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
|
EP4399302A2
(en)
|
2021-09-08 |
2024-07-17 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
|
CA3230927A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
|
EP4408996A2
(en)
|
2021-09-30 |
2024-08-07 |
Astrazeneca AB |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
EP4416292A2
(en)
|
2021-10-14 |
2024-08-21 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
EP4405463A1
(en)
|
2021-10-14 |
2024-07-31 |
Lonza Sales AG |
Modified producer cells for extracellular vesicle production
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
IL312452A
(en)
|
2021-11-01 |
2024-06-01 |
Tome Biosciences Inc |
A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo
|
|
US20250302874A1
(en)
|
2021-11-03 |
2025-10-02 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
JP2024542995A
(ja)
|
2021-11-03 |
2024-11-19 |
インテリア セラピューティクス，インコーポレイテッド |
ゲノム編集のためのポリヌクレオチド、組成物、及び方法
|
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
US20250057980A1
(en)
|
2021-12-22 |
2025-02-20 |
Tome Biosciences, Inc. |
Co-Delivery of a Gene Editor Construct and a Donor Template
|
|
CN119325508A
(zh)
|
2021-12-29 |
2025-01-17 |
百时美施贵宝公司 |
着陆垫细胞系的生成
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
US20250032642A1
(en)
|
2022-02-02 |
2025-01-30 |
Regeneron Pharmaceuticals, Inc. |
Crispr-mediated transgene insertion in neonatal cells
|
|
WO2023172927A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy
|
|
EP4490291A1
(en)
|
2022-03-08 |
2025-01-15 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
EP4514981A2
(en)
|
2022-04-29 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
|
CN119604610A
(zh)
|
2022-05-09 |
2025-03-11 |
瑞泽恩制药公司 |
用于体内抗体产生的载体和方法
|
|
KR20250027283A
(ko)
|
2022-05-19 |
2025-02-25 |
라이엘 이뮤노파마, 인크. |
nr4a3을 표적하는 폴리뉴클레오타이드 및 이의 용도
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
|
MA71557A
(fr)
|
2022-07-18 |
2025-05-30 |
Renagade Therapeutics Management Inc. |
Composants d'édition génique, systèmes et procédés d'utilisation
|
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
CA3261203A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
|
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
|
EP4593872A1
(en)
|
2022-09-28 |
2025-08-06 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
JP2025538220A
(ja)
|
2022-11-14 |
2025-11-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
|
|
AU2023409139A1
(en)
|
2022-12-21 |
2025-05-22 |
Intellia Therapeutics, Inc. |
Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
IL321908A
(en)
|
2023-01-27 |
2025-09-01 |
Regeneron Pharma |
Different rhabdomyovirus glycoproteins and their use
|
|
WO2024186890A1
(en)
|
2023-03-06 |
2024-09-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for hepatitis b virus (hbv) genome editing
|
|
EP4677067A1
(en)
|
2023-03-07 |
2026-01-14 |
Intellia Therapeutics, Inc. |
Cish compositions and methods for immunotherapy
|
|
WO2024201368A1
(en)
|
2023-03-29 |
2024-10-03 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024275548A1
(en)
|
2023-05-19 |
2026-01-08 |
Intellia Therapeutics, Inc. |
Ionizable amine lipids
|
|
WO2024259309A1
(en)
|
2023-06-15 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Gene therapy for hearing disorders
|
|
AU2024309884A1
(en)
|
2023-06-30 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
AU2024317483A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
AU2024315073A1
(en)
|
2023-07-28 |
2026-01-22 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
AU2024317508A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025027166A1
(en)
|
2023-08-01 |
2025-02-06 |
Basf Plant Science Company Gmbh |
Increased resistance by expression of msbp1 protein
|
|
WO2025027165A1
(en)
|
2023-08-01 |
2025-02-06 |
Basf Plant Science Company Gmbh |
Increased resistance by expression of an ics protein
|
|
WO2025038642A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying cd70
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025038750A2
(en)
|
2023-08-14 |
2025-02-20 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
|
WO2025038648A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
TW202521564A
(zh)
|
2023-08-14 |
2025-06-01 |
美商英特利亞醫療公司 |
用於基於細胞之療法的ｃｄ７０ ｃａｒ－ｔ組合物及方法
|
|
WO2025049481A1
(en)
|
2023-08-28 |
2025-03-06 |
Intellia Therapeutics, Inc. |
Methods of editing an hla-a gene in vitro
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025078978A1
(en)
|
2023-10-09 |
2025-04-17 |
Avectas Limited |
Transfection of cells via reversible permeabilization
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025111340A1
(en)
*
|
2023-11-20 |
2025-05-30 |
William Marsh Rice University |
Engineered extrachromosomal nucleic acids and methods of use thereof
|
|
WO2025149983A2
(en)
|
2024-01-12 |
2025-07-17 |
Avectas Limited |
Delivery platform with integrated non-viral transfection and cell processing
|
|
WO2025149984A2
(en)
|
2024-01-12 |
2025-07-17 |
Avectas Limited |
Delivery platform with flow-through system (fts)
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025162985A1
(en)
|
2024-01-30 |
2025-08-07 |
Basf Plant Science Company Gmbh |
Increased plant disease resistance by expression of a glycine-rich protein
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025202473A1
(en)
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
WO2025217398A1
(en)
|
2024-04-10 |
2025-10-16 |
Lyell Immunopharma, Inc. |
Methods for culturing cells with improved culture medium
|
|
WO2025224107A1
(en)
|
2024-04-22 |
2025-10-30 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
WO2025259669A1
(en)
|
2024-06-10 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for characterizing modified oligonucleotides
|
|
US20250388890A1
(en)
|
2024-06-20 |
2025-12-25 |
Regeneron Pharmaceuticals, Inc. |
ASS1 Gene Insertion For The Treatment Of Citrullinemia Type I
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|